Delisting risk
Kairos Pharma (KAPA)
Develops resistance-focused cancer therapies led by ENV-105.
$1.54
Pre-market−0.07 (−4.35%)
At close$1.61(−2.42%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions11 holders · as of Mar 31, 2026 | 2.54% | 85.9K shares | |
| Otherremainder | 97.46% | 3.30M shares |
3.39M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (3.39M in the company's Sep 3, 2026 report, 3.06M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
11 holders · 601.1K shares · 4 new positions · 6 increased · 2 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 231.9K | 6.85% | +231.9Knew | May 15, 2026 |
| Geode Capital Management, LLC | 111.3K | 3.29% | +38.5K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 63.9K | 1.89% | +63.9Knew | May 8, 2026 |
| Sevenbridge Financial Group, LLC | 44.3K | 1.31% | 0 | Apr 23, 2026 |
| Aptus Capital Advisors, LLC | 44.3K | 1.31% | 0 | May 11, 2026 |
| Two Sigma Investments, LP | 39.5K | 1.17% | −54.5K | May 15, 2026 |
| State Street Corp | 24.1K | 0.71% | 0 | May 15, 2026 |
| HRT Financial LP | 21.6K | 0.64% | +256 | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.